Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis?

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Santoni, Matteo ^a   Conti, Alessandro ^a   Procopio, Giuseppe ^b   Porta, Camillo ^c   Ibrahim, Toni ^d   Barni, Sandro ^e   Guida, Francesco Maria ^f   Fontana, Andrea ^g   Berruti, Alfredo ^h   Berardi, Rossana ^a   Massari, Francesco ⁱ   Vincenzi, Bruno ^f   Ortega, Cinzia ^j   Ottaviani, Davide ^k   Carteni, Giacomo ^l   Lanzetta, Gaetano ^m,n   De Lisi, Delia ^f   Silvestris, Nicola ^o   Satolli, Maria Antonietta ^p   Collovà, Elena ^q   Russo, Antonio ^r   Badalamenti, Giuseppe ^r   Fedeli, Stefano Luzi ^a   Tanca, Francesca Maria ^s   Adamo, Vincenzo ^t   Maiello, Evaristo ^u   Sabbatini, Roberto ^v   Felici, Alessandra ^w   Cinieri, Saverio ^x   Montironi, Rodolfo ^a   Bracarda, Sergio ^y   Tonini, Giuseppe ^f   Cascinu, Stefano ^a   Santini, Daniele ^f   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e TREVIGLIO HOSPITAL   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g ISTITUTO TOSCANO TUMORI   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF VERONA   (Italy)

^j CANDIOLO CANCER INSTITUTE   (Italy)

^k GRADENIGO HOSPITAL   (Italy)

^l CARDARELLI HOSPITAL   (Italy)

^m IRCCS NEUROMED   (Italy)

ⁿ Istituto Neurotraumatologico Italiano   (Italy)

^o NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^p UNIVERSITY OF TURIN   (Italy)

^q Hospital of Legnano   (Italy)

^r UNIVERSITY OF PALERMO   (Italy)

^s UNIVERSITY OF CAGLIARI   (Italy)

^t UNIVERSITY OF MESSINA   (Italy)

^u CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^v UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^w REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^x EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^y IRCCS POLICLINICO SAN DONATO   (Italy)

more..

Author keywords

Bone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISTANT METASTASIS; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BONE TUMOR; CLINICAL TRIAL; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84924098220     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0122-0     Document Type: Article

References (29)

1. Murai M, Oya M. Renal cell carcinoma: Etiology, incidence and epidemiology. Curr Opin Urol. 2004; 14: 229-33.
2. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: A review. Can J Urol. 2008; 15: 3954-66.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335: 865-75.
4. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011; 48: 160-6.
5. Sahi C, Knox JJ, Clemons M, Joshua AM, Broom R. Renal cell carcinoma bone metastases: Clinical advances. Ther Adv Med Oncol. 2010; 2: 75-83.
6. Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res. 2007; 26: 307-12.
7. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, et al. Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey. PLoS One. 2013; 8: E83026.
8. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2011; 22: 794-800.
9. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-Targeted therapy. Cancer. 2007; 110: 543-50.
10. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-92.
11. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, et al. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: Suggestions from bench to bedside. Cancer Metastasis Rev. 2014; 33: 321-31.
12. Newcombe RG. Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med. 1998; 17: 873-90.
13. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454-63.
14. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-9.
15. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014; 65: 1086-92.
16. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, et al. Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. J Urol. 2015; 193: 41-7. doi: 10.1016/j.juro.2014.07.011.
17. Hosmer WJ, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley; 1999.
18. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003; 9: 2587-97.
19. Shiirevnyamba A, Takahashi T, Shan H, Ogawa H, Yano S, Kanayama H, et al. Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. Br J Cancer. 2011; 104: 505-13.
20. Chen Y, Liu H, Wu W, Li Y, Li J. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res. 2013; 32: 45.
21. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000; 10: 159-78.
22. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-93.
23. Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, et al. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9: E89880.
24. Joeckel E, Haber T, Prawitt D, Junker K, Hampel C, Thüroff JW, et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol Cancer. 2014; 13: 42.
25. Yang L, You S, Kumar V, Zhang C, Cao Y. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. J Exp Clin Cancer Res. 2012; 31: 40.
26. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R. Choueiri. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma Eur Urol. 2014; 66: 502-9.
27. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, et al. Sorafenib for metastatic renal cancer: The Princess Margaret experience. Am J Clin Oncol. 2008; 31: 182-7.
28. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G, et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004; 10: 6397S-403.
29. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer. 2012; 48: 1031-7.